Biogen Inc.

Report azionario NasdaqGS:BIIB

Capitalizzazione di mercato: US$27.6b

Biogen Crescita futura

Criteri Future verificati 1/6

Biogen prevede che gli utili e i ricavi cresceranno rispettivamente di 13.9% e 2.4% all'anno. Si prevede che l'EPS crescerà di 14.4% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 12.5% in 3 anni.

Informazioni chiave

13.9%

Tasso di crescita degli utili

14.43%

Tasso di crescita dell'EPS

Biotechs crescita degli utili24.1%
Tasso di crescita dei ricavi2.4%
Rendimento futuro del capitale proprio12.51%
Copertura analitica

Good

Ultimo aggiornamento04 May 2026

Aggiornamenti recenti sulla crescita futura

Recent updates

BIIB: 2026 Readouts In Neurology And Immunology Will Drive Upside Potential

Analysts have lifted Biogen's fair value estimate by about $18 to $273.20 as they factor in updated revenue growth assumptions, a higher future P/E, and recent price target revisions across the Street. Analyst Commentary Recent Street research around Biogen has leaned constructive, with a cluster of fresh price target adjustments and several rating upgrades pointing to improving sentiment on execution and long term growth potential.

BIIB: 2026 Trial Outcomes Will Likely Undermine Recent Acquisition Optimism

Analysts made a slight upward adjustment to Biogen's fair value estimate to about $151, reflecting a blend of higher and lower price target revisions related to recent acquisition activity, pipeline updates, and shifting views on its long term earnings profile. Analyst Commentary Recent Street research around Biogen has been active, with a mix of higher and lower price targets clustered around the company’s acquisition activity, pipeline readouts, and changing expectations for longer term earnings power.

Revisiting Eisai And Biogen's Leqembi Data For Alzheimer's Disease

Apr 06

BIIB: 2026 Clinical Outcomes Will Likely Challenge Recent Neuroscience Optimism

The analyst price target for Biogen has been adjusted slightly to $150. This reflects recent model updates that incorporate a modestly higher discount rate, slightly lower revenue growth assumptions, a small uptick in expected profit margins, and Street research focusing on price target changes and evolving views on the company's pipeline and neurology portfolio.

Biogen Inc. (BIIB): The "Post-MS" Pivot and the Alzheimer’s Momentum

Biogen Inc. (BIIB) is navigating a high-stakes transition year in 2026, closing the March 31, 2026, session at $178.98 USD on the NASDAQ.

BIIB: 2026 Clinical Readouts Will Likely Undermine Recent Pipeline Optimism

Analysts have nudged Biogen's fair value estimate higher to $151.48 from $147.47, reflecting a series of recent price target increases across the Street and ongoing reassessments of the company's pipeline and commercial outlook. Analyst Commentary Recent Street research around Biogen points to a mixed setup, with several firms adjusting price targets and ratings as they reassess the pipeline, commercial execution, and sector positioning.

BIIB: 2026 Clinical Readouts And Easing Policy Risks Will Drive Upside

The analyst fair value estimate for Biogen has increased by about $16 to $205.67 as analysts factor in recent price target revisions and updated views on the pipeline and commercial outlook. Analyst Commentary Recent research updates on Biogen cluster around revisions to price targets, refreshed models on the pipeline, and differing expectations for execution in 2026 and beyond.

BIIB: 2026 Clinical Readouts Will Likely Expose Pipeline Execution Risk

The analyst price target for Biogen has been raised from $143.00 to $147.47. Analysts point to a stronger profit margin outlook and updated pipeline and commercial assumptions as key drivers of the change.

There May Be Reason For Hope In Biogen's (NASDAQ:BIIB) Disappointing Earnings

Feb 13
There May Be Reason For Hope In Biogen's (NASDAQ:BIIB) Disappointing Earnings

BIIB: 2026 Clinical Readouts And Pipeline Execution Will Drive Upside Potential

Analysts have nudged their price targets on Biogen higher, with our fair value estimate rising to about $255.45 from $247.88 as they update models for revenue growth, margins, and a modestly richer future P/E multiple following a series of mixed but generally upward target revisions across the Street. Analyst Commentary Recent research on Biogen has been mixed, but the pricing and modeling changes skew toward a constructive tone.

BIIB: 2026 Clinical Readouts Will Test Lofty Pipeline Expectations

Analysts have raised their Biogen fair value estimate from $128.00 to $143.00, citing refreshed models and higher Street price targets as they incorporate updated views on the pipeline, sector conditions, and 2026 catalysts. Analyst Commentary Street research around Biogen points to a generally more constructive view on the shares, with several firms lifting price targets into a range between about $180 and $225.

BIIB: Easing Policy Shifts And 2026 Pipeline Readouts Will Shape Outlook

Narrative Update: Biogen (BIIB) Biogen's fair value estimate has moved from about $181 to around $190 as analysts lift price targets into the $180 to $225 range and highlight updated models, slightly better margin and growth assumptions, and potential pipeline and sector catalysts through 2026. Analyst Commentary Recent research updates on Biogen cluster around a tighter valuation band in the high US$100s to low US$200s, with most firms revisiting their models and assumptions for 2025 to 2026.

BIIB: Easing Policy Overhangs And Alzheimer’s Data Will Shape Risk Reward Balance

Analysts have modestly raised their price target on Biogen, now implying upside in line with a slightly higher fair value of approximately $181, citing easing policy overhangs and a partial rerating of large-cap biopharma as investor focus shifts back to fundamentals. Analyst Commentary Street research on Biogen has turned incrementally more constructive, with several firms lifting price targets as macro and policy risks appear less threatening to the sector.

BIIB: Policy Environment And Late-Stage Pipeline Will Shape Risk And Reward Ahead

Analysts have modestly increased their price target for Biogen, lifting fair value by about $1 to roughly $179 per share. They cite easing policy overhangs, growing confidence in 2025 to 2026 fundamentals, and potential upside from Leqembi and the broader late stage pipeline.

BIIB: Policy Shifts And Drug Pipeline Progress Will Influence Risk And Reward Ahead

Biogen's analyst price target has been increased modestly, with the fair value estimate rising from $176.72 to $178.07. Analysts point to easing policy headwinds and renewed focus on company fundamentals amid recent sector re-ratings.

BIIB: Pipeline And Policy Developments Will Shape Risk And Reward Into 2025

Analysts have raised their price target for Biogen by approximately $4 to $176.72, citing improving sector fundamentals, easing policy risks, and a favorable risk/reward outlook as reasons for the adjustment. Analyst Commentary Recent street research on Biogen provides insight into both the optimistic and cautious perspectives that currently shape the stock's outlook.

Easing Policy Risks And New Therapy Launches Will Drive Shares Higher

Analysts have slightly raised their price target for Biogen to $172.55 from $172.34, reflecting modestly improved revenue growth expectations and an easing policy backdrop in the biotech sector. Analyst Commentary Recent street research reveals a spectrum of opinions around Biogen, highlighted by both bullish and bearish analyst actions.

Expanding Global Healthcare And Diagnostics Infrastructure Will Drive Future Growth

Analysts have slightly lifted their price targets for Biogen, with the updated fair value estimate rising from $170.03 to $172.34. This reflects improved profit margin expectations and easing industry headwinds cited in recent research updates.

Expanding Global Healthcare And Diagnostics Infrastructure Will Drive Future Growth

Biogen's modestly reduced consensus price target reflects a balanced analyst view, with optimism around strong Q2 performance, pipeline progress, and portfolio refocusing offset by lingering regulatory overhangs and a muted near-term growth outlook, resulting in a slight decrease in fair value from $171.96 to $170.03. Analyst Commentary Bullish analysts cite strong Q2 performance, particularly from Leqembi and the MS franchise, as well as solid sales across other programs as drivers for raised price targets.

Expanding Global Healthcare And Diagnostics Infrastructure Will Drive Future Growth

Biogen’s consensus price target was modestly raised as analysts highlighted strong Q2 performance, advancements in its neuro portfolio and pipeline, and ongoing portfolio refocusing, offsetting medium-term growth concerns and regulatory risks; the new fair value is now $171.96. Analyst Commentary Bullish analysts highlight strong Q2 performance, particularly in Leqembi and the MS franchise, combined with solid sales across other programs, supporting upward revisions in price targets.

Biogen (NASDAQ:BIIB) Seems To Use Debt Quite Sensibly

Jun 17
Biogen (NASDAQ:BIIB) Seems To Use Debt Quite Sensibly

Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent?

Apr 25

Biogen: Balancing Risks And Opportunities

Mar 27

Biogen Q4 Earnings Review: Why I'm Calling Time On This 'Powder Puff' Pharma

Feb 15

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:BIIB - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/202810,6082,1342,4063,32217
12/31/202710,3171,9292,5742,63622
12/31/202610,0121,1402,6971,84222
3/31/20269,9371,3722,3162,591N/A
12/31/20259,8911,2931,9692,205N/A
9/30/202510,0661,6092,2622,454N/A
6/30/20259,9971,5311,8322,117N/A
3/31/20259,8161,4792,3842,582N/A
12/31/20249,6761,6322,6042,876N/A
9/30/20249,6081,6151,8572,127N/A
6/30/20249,6721,1591,5711,784N/A
3/31/20249,6631,1671,2841,645N/A
12/31/20239,8361,1611,2361,547N/A
9/30/20239,9931,4621,0261,360N/A
6/30/20239,9722,6651,1231,428N/A
3/31/202310,1053,1311,4211,678N/A
12/31/202210,1733,0471,1411,384N/A
9/30/202210,3632,8652,1732,398N/A
6/30/202210,6342,0592,3152,542N/A
3/31/202210,8201,4502,7733,033N/A
12/31/202110,9821,5563,3453,640N/A
9/30/202111,1011,5462,1072,435N/A
6/30/202111,6981,9182,4612,810N/A
3/31/202112,6043,0123,1493,532N/A
12/31/202013,4454,0013,6784,230N/A
9/30/202014,2635,0825,8416,557N/A
6/30/202014,4875,9276,3497,071N/A
3/31/202014,4225,8796,2827,086N/A
12/31/201914,3785,889N/A7,079N/A
9/30/201914,2335,396N/A7,014N/A
6/30/201914,0725,294N/A7,055N/A
3/31/201913,8124,667N/A6,190N/A
12/31/201813,4534,431N/A6,188N/A
9/30/201813,2343,187N/A5,811N/A
6/30/201812,8722,968N/A5,703N/A
3/31/201812,5942,964N/A5,773N/A
12/31/201712,2742,539N/A4,551N/A
9/30/201711,8393,486N/A4,615N/A
6/30/201711,7173,293N/A3,978N/A
3/31/201711,5333,480N/A3,807N/A
12/31/201611,4493,703N/A4,587N/A
9/30/201611,4163,885N/A4,046N/A
6/30/201611,2383,818N/A3,950N/A
3/31/201610,9363,695N/A3,999N/A
12/31/201510,7643,547N/A3,919N/A
9/30/201510,5653,599N/A3,609N/A
6/30/201510,2993,490N/A3,627N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di BIIB ( 13.9% all'anno) è superiore al tasso di risparmio ( 3.5% ).

Guadagni vs Mercato: Si prevede che gli utili di BIIB ( 13.9% all'anno) cresceranno più lentamente rispetto al mercato US ( 16.1% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di BIIB cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di BIIB ( 2.4% all'anno) crescerà più lentamente rispetto al mercato US ( 11.3% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di BIIB ( 2.4% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di BIIB sarà basso tra 3 anni ( 12.5 %).

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/05 18:58
Prezzo dell'azione a fine giornata2026/05/05 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Biogen Inc. è coperta da 58 analisti. 22 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
David ToungArgus Research Company
Brian SkorneyBaird
Emily FieldBarclays